Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network

Cardiol Therapeutics Inc. announced the expansion of its pivotal Phase III MAVERIC trial in the United States, with plans to activate up to seven additional clinical centers. Patient enrollment in the trial has reached 75%, with target recruitment anticipated by the end of Q2 2026. The MAVERIC trial evaluates CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. The trial builds on positive Phase II data and is designed to support a New Drug Application with the U.S. FDA. The company also noted the growing interest from leading clinical centers and the unmet need in recurrent pericarditis. Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with CardiolRx™ being its lead small-molecule drug candidate.